Sanofi SA/ FR0000120578 /
2024-04-26 2:22:03 PM | Chg. -1.220 | Volume | Bid2024-04-26 | Ask2:22:03 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
90.400EUR | -1.33% | 435,461 Turnover: 39.2 mill. |
90.390Bid Size: 4 | 90.410Ask Size: 122 | 113.29 bill.EUR | 4.16% | 20.97 |
GlobeNewswire
04-25
International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on A...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
04-23
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire
04-17
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire
04-10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
04-09
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire
03-14
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Busi...
GlobeNewswire
03-14
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
GlobeNewswire
03-11
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance ...
GlobeNewswire
03-05
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (F...
GlobeNewswire
02-28
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized ...
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-24
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significa...
GlobeNewswire
02-23
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” co...